Primary and secondary outcomes, by diabetes status
diabetes
EVENT, SECONDARY, DIABETES
In the placebo arm, the adjusted, annualized event rate for the primary outcome was nominally higher in patients with diabetes than in patients without diabetes (66.9 vs 54.3 per 100 patient-years; RR: 1.23, 95% CI 0.88–1.72); similar results were observed for secondary outcomes (Additional file Regarding treatment effect, reductions in annualized event rates with FCM vs placebo were observed in patients both with and without diabetes (Fig. Primary and secondary outcomes with FCM vs placebo in patients with and without diabetes. mITT population analyzed. All models adjusted for covariates: sex, age, HF etiology, HF duration, country, and diabetes status at baseline, and diabetes at baseline × treatment. N = 1108 for all patients. Respective n-values in patients with and without diabetes at baseline were 231 and 327 for FCM and 244 and 306 for placebo. 